Список литературы к Главе 6

93. Москалев Е.А. Аномальные изменения картины метилирования геномной ДНК при хроническом B­клеточном лимфолейкозе : дис. … канд. биол. наук. Воронеж, 2007.

94. Mund C., Beier V., Bewerunge P., Dahms M., Lyko F., Hoheisel J.D. Array­based analysis of genomic DNA methylation patterns of the tumour suppressor gene p16INK4A promoter in colon carcinoma cell lines // Nucleic Acids Res. 2005. Vol. 33. P. e73.

95. Garding A., Bhattacharya N., Claus R., Ruppel M., Tschuch C., Filarsky K. et al. Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downregulation of a gene cluster that targets NF­kB // PLoS Genet. 2013. Vol. 9. Article ID e1003373.

96. Subhash S., Andersson P.O., Kosalai S.T., Kanduri C., Kanduri M. Global DNA methylation profiling reveals new insights into epigenetically deregulated protein coding and long noncoding RNAs in CLL // Clin. Epigenetics. 2016. Vol. 8. P. 106.

97. Chen Y.A., Choufani S., Ferreira J.C., Grafodatskaya D., Butcher D.T., Weksberg R. Sequence overlap between autosomal and sex­linked probes on the Illumina HumanMethylation27 microarray // Genomics. 2011. Vol. 97. P. 214–222.

98. Sandoval J., Heyn H., Moran S., Serra­Musach J., Pujana M.A., Bibikova M. et al. Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome // Epigenetics. 2011. Vol. 6. P. 692–702.

99. Mansouri L., Wierzbinska J.A., Plass C., Rosenquist R. Epigenetic deregulation in chronic lymphocytic leukemia: clinical and biological impact // Semin. Cancer Biol. 2018. Vol. 51. P. 1–11.

100. Kanduri M., Cahill N., Goransson H., Enstrom C., Ryan F., Isaksson A. et al. Differential genome­wide array­based methylation profiles in prognostic subsets of chronic lymphocytic leukemia // Blood. 2010. Vol. 115. P. 296–305.

101. Cahill N., Bergh A.C., Kanduri M., Goransson­Kultima H., Mansouri L., Isaksson A. et al. 450K­array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments // Leukemia. 2013. Vol. 27. P. 150–158.

102. Baliakas P., Mattsson M., Stamatopoulos K., Rosenquist R. Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed? // J. Intern. Med. 2016. Vol. 279. P. 347–357.

103. Rosenquist R., Cortese D., Bhoi S., Mansouri L., Gunnarsson R. Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand? // Leuk. Lymphoma. 2013. Vol. 54. P. 2351–2364.

104. Dohner H., Stilgenbauer S., Benner A., Leupolt E., Krober A., Bullinger L. et al. Genomic aberrations and survival in chronic lymphocytic leukemia // N. Engl. J. Med. 2000. Vol. 343. P. 1910–1916.

105. Malcikova J., Tausch E., Rossi D., Sutton L.A., Soussi T., Zenz T. et al. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia­update on methodological approaches and results interpretation // Leukemia. 2018. Vol. 32. P. 1070–1080.

106. Claus R., Lucas D.M., Stilgenbauer S., Ruppert A.S., Yu L., Zucknick M. et al. Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP­70 expression and predictive of prognosis in chronic lymphocytic leukemia // J. Clin. Oncol. 2012. Vol. 30. P. 2483–2491.

107. Daugaard I., Hussmann D., Kristensen L., Kristensen T., Kjeldsen T.E., Nyvold C.G. et al. Chronic lymphocytic leukemia patients with heterogeneously or fully methylated LPL promotor display longer time to treatment // Epigenomics. 2018. Vol. 10. P. 1155–1166.

108. Shinawi T., Hill V., Dagklis A., Baliakas P., Stamatopoulos K., Agathanggelou A. et al. KIBRA gene methylation is associated with unfavorable biological prognostic parameters in chronic lymphocytic leukemia // Epigenetics. 2012. Vol. 7. P. 211–215.

109. Irving L., Mainou­Fowler T., Parker A., Ibbotson R.E., Oscier D.G., Strathdee G. Methylation markers identify high risk patients in IGHV mutated chronic lymphocytic leukemia // Epigenetics. 2011. Vol. 6. P. 300–306.

110. Stamatopoulos K., Belessi C., Moreno C., Boudjograh M., Guida G., Smilevska T. et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations // Blood. 2007. Vol. 109. P. 259–270.

111. Blum K.A., Liu Z., Lucas D.M., Chen P., Xie Z., Baiocchi R. et al. Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non­Hodgkin lymphoma: dose­limiting myelosuppression without evidence of DNA hypomethylation // Br. J. Haematol. 2010. Vol. 150. P. 189–195.

112. Malik A., Shoukier M., Garcia­Manero G., Wierda W., Cortes J., Bickel S. et al. Azacitidine in fludarabine­refractory chronic lymphocytic leukemia: a phase II study // Clin. Lymphoma Myeloma Leuk. 2013. Vol. 13. P. 292–295.

113. Bokelmann I., Mahlknecht U. Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro­ and antiapoptotic proteins // Mol. Med. 2008. Vol. 14. P. 20–27.

114. Peiffer L., Poll­Wolbeck S.J., Flamme H., Gehrke I., Hallek M., Kreuzer K.A. Trichostatin A effectively induces apoptosis in chronic lymphocytic leukemia cells via inhibition of Wnt signaling and histone deacetylation // J. Cancer Res. Clin. Oncol. 2014. Vol. 140. P. 1283–1293.

115. Aron J.L., Parthun M.R., Marcucci G., Kitada S., Mone A.P., Davis M.E. et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8­mediated apoptosis and down­regulation of c­FLIP protein // Blood. 2003. Vol. 102. P. 652–658.

116. Byrd J.C., Shinn C., Ravi R., Willis C.R., Waselenko J.K., Flinn I.W. et al. Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B­cell chronic lymphocytic leukemia cells // Blood. 1999. Vol. 94. P. 1401–1408.

117. Byrd J.C., Marcucci G., Parthun M.R., Xiao J.J., Klisovic R.B., Moran M. et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia // Blood. 2005. Vol. 105. P. 959–967.

118. Bonfils C., Kalita A., Dubay M., Siu L.L., Carducci M.A., Reid G. et al. Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay // Clin. Cancer Res. 2008. Vol. 14. P. 3441–3449.

119. El­Khoury V., Moussay E., Janji B., Palissot V., Aouali N., Brons N.H. et a;. The histone deacetylase inhibitor MGCD0103 induces apoptosis in B­cell chronic lymphocytic leukemia cells through a mitochondria­mediated caspase activation cascade // Mol. Cancer Ther. 2010. Vol. 9. P. 1349–1360.

120. Blum K.A., Advani A., Fernandez L., Van Der Jagt R., Brandwein J., Kambhampati S. et al. Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia // Br. J. Haematol. 2009. Vol. 147. P. 507–514.

121. Gutierrez A. Jr, Tschumper R.C., Wu X., Shanafelt T.D., Eckel­Passow J., Huddleston P.M. 3rd et al. LEF­1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B­cell lymphocytosis // Blood. 2010. Vol. 116. P. 2975–2983.

122. Georgiadis P., Liampa I., Hebels D.G., Krauskopf J., Chatziioannou A., Valavanis I. et al. Evolving DNA methylation and gene expression markers of B­cell chronic lymphocytic leukemia are present in pre­diagnostic blood samples more than 10 years prior to diagnosis // BMC Genomics. 2017. Vol. 18. P. 728.

123. Herceg Z., Vaissiere T. Epigenetic mechanisms and cancer: an interface between the environment and the genome // Epigenetics. 2011. Vol. 6. P. 804–819.